Comparison of treatment outcomes of ticagrelor and clopidogrel among patients undergoing percutaneous coronary intervention: A meta-analysis

Abstract

We performed a meta-analysis of randomized controlled trials (RCTs) to investigate the efficacy and safety of ticagrelor (TIC) vs. clopidogrel (CLO) in patients undergoing percutaneous coronary intervention (PCI). In Jun 2016, a literature search was started and all the studies were conducted from 2010 to 2015. We systematically searched the literature through the MEDLINE database, Cochrane library, and EMBASE database. Quality assessments were evaluated with Jadad quality scale. Data were extracted considering the characteristics of efficacy and safety designs. Six RCTs enrolling 26 244 participants and satisfying the inclusion criteria were finally analyzed. There was a significant decrease of all-cause mortality (MD=0.83, 95%CI=0.74–0.93, P=0.001) and myocardial infarction (MI) (MD=0.78, 95%CI=0.70–0.88, P=0.000). There were no significant differences in stroke (MD=1.34, 95%CI=0.99–1.79, P=0.06), total bleeding (MD=0.97, 95%CI=0.84–1.12, P=0.66), minor or major bleeding (MD=1.06, 95%CI=0.94–1.19, P=0.35) in patients undergoing PCI after treatment with TIC vs. CLO. TIC could be more significant in decreasing all-cause mortality and MI than CLO, but there were no significant differences between TIC and CLO in inhibiting stroke, major bleeding, major or minor bleeding in patients undergoing PCI.

Keywords

ticagrelor / clopidogrel / percutaneous coronary intervention / outcomes / meta-analysis

References

[1] BaberU, MehranR, GiustinoG, et al. . Coronary thrombosis and major bleeding after pci with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol, 2016, 67(19): 2224-2234 PMID: 27079334

[2] LevineGN, BatesER, BlankenshipJC, et al. . 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol, 2011, 58(24): 2550-2583

[3] SatturS, OrshawP, BouraJ, et al. . Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents in st elevation myocardial infarction: Findings from the guthrie health off-label stent (ghost) registry. J Interv Cardiol, 2012, 25(2): 118-125 PMID: 22324820

[4] XuL, HuXW, ZhangSH, et al. . Intensified antiplatelet treatment reduces major cardiac events in patients with clopidogrel low response: a meta-analysis of randomized controlled trials. Chin Med J (Engl), 2016, 129(8): 984-991

[5] Bellemain-AppaixA, O'ConnorSA, SilvainJ, et al. . Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis. JAMA, 2012, 308(23): 2507-2516 PMID: 23287889

[6] GachetC. ADP receptors of platelets and their inhibition. Thromb Haemost, 2001, 86(86): 222-232 PMID: 11487010

[7] GurbelPA, AthanK, TantryUS. G-protein-coupled receptors signaling pathways in new antiplatelet drug development. Arterioscler Thromb Vasc Biol, 2015, 35(3): 500-512 PMID: 25633316 PMCID: 4836833

[8] VeldersMA, AbtanJ, AngiolilloDJ, et al. . Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart, 2016, 102(8): 617-625 PMID: 26848185

[9] AngiolilloDJ, FranchiF, WaksmanR, et al. . Effects of ticagrelor versus clopidogrel in troponin-negative patients with low-risk ACS undergoing ad hoc PCI. J Am Coll Cardiol, 2016, 67(6): 603-613 PMID: 26868683

[10] GanXD, WeiBZ, FangD, et al. . Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis. Curr Med Res Opin, 2015, 31(12): 2313-2323 PMID: 26402735

[11] StegPG, JamesS, HarringtonRA, et al. . Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation, 2010, 122(21): 2131-2141 PMID: 21060072

[12] BonelloL, FrereC, CointeS, et al. . Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study. Int J Cardiol, 2015, 187(1): 502-507 PMID: 25846661

[13] CannonCP, HarringtonRA, JamesS, et al. . Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet, 2010, 375(9711): 283-293 PMID: 20079528

[14] ZhuK, FuQ, ZhangN, et al. . Pre-PCI medication using clopidogrel and ticagrelor in the treatment of patients with acute myocardial infarction. Eur Rev Med Pharmacol Sci, 2015, 19(23): 4636-4641 PMID: 26698262

[15] XiaJG, QuY, HuSD, et al. . Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Beijing Da Xue Xue Bao (Chinese), 2015, 47(3): 494-498

[16] WihlborgAK, WangL, BraunOO, et al. . ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol, 2004, 24(10): 1810-1815 PMID: 15308557

[17] GrzeskG, KozinskiM, NavareseEP, et al. . Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. Thromb Res, 2012, 130(1): 65-69 PMID: 22265722

[18] OhmanJ, KudiraR, AlbinssonS, et al. . Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun, 2012, 418(4): 754-758 PMID: 22306816

[19] Van GiezenJJ, SidawayJ, GlavesP, et al. . Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther, 2012, 17(2): 164-172 PMID: 21697355

[20] BhavarajuK, GeorgakisA, JinJ, et al. . Antagonism of P2Y12 reduces physiological thromboxane levels. Platelets, 2010, 21(8): 604-609 PMID: 21067313

[21] WallentinL, BeckerRC, BudajA, et al. . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009, 361(11): 1045-1057 PMID: 19717846

[22] GotoS, HuangCH, ParkSJ, et al. . Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome—randomized, double-blind, phase III PHILO study. Circ J, 2015, 79(11): 2452-2460 PMID: 26376600

[23] GurbelPA, BlidenKP, ButlerK, et al. . Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation, 2009, 120(25): 25775-25785

[24] LiZ, LiY, ZhangT, et al. . Comparison of the influence of ticagrelor and clopidogrel on inflammatory biomarkers and vascular endothelial function for patients with ST-segment elevation myocardial infarction receiving emergency percutaneous coronary intervention: study protocol for a randomized controlled trial. Trials, 2016, 17(1): 75 PMID: 26865043 PMCID: 4750211

[25] HustedS, StoreyRF, HarringtonRA, et al. . Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol, 2010, 33(4): 206-212 PMID: 20394040